The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTPG.L Regulatory News (TPG)

  • There is currently no data for TPG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Court Sanction of Scheme of Arrangement

24 Jan 2023 14:21

RNS Number : 7284N
TP Group PLC
24 January 2023
 

24 January 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

RECOMMENDED CASH ACQUISITION

of

TP Group plc("TP Group" or the "Company")

by

Science Group plc("Science Group")

to be effected by way of scheme of arrangementunder Part 26 of the Companies Act 2006 ("Companies Act")

COURT SANCTION OF SCHEME OF ARRANGEMENT

Further to the Company's announcement on 9 January 2023 regarding the proposed final timetable leading to completion of the Scheme, the Company announces that Science Group has waived the final outstanding condition relating to the receipt of FATA clearance and the Court has today sanctioned the Scheme. Accordingly, the Scheme will become effective on 26 January 2023 (the "Effective Date") once the Court Order has been delivered to the Registrar of Companies. As previously announced, the last day of dealings in the Shares will be tomorrow, 25 January 2023, and the Shares will be suspended from trading on AIM at 7.30 a.m. (London time) on 26 January 2023, being the Effective Date. Cancellation of admission to trading on AIM of the Shares is expected to take place by 7.00 a.m. on 27 January 2023. Following the Scheme becoming Effective, TP Group will be re-registered as a private company limited by shares under the relevant provisions of the Companies Act.

A further announcement will be made when the Scheme becomes Effective.

Capitalised terms used in this announcement (the "Announcement") shall, unless otherwise defined, have the same meanings as set out in the scheme document dated 21 November 2022.

All references to times in this Announcement are to London, United Kingdom times unless stated otherwise.

Enquiries:

TP Group plc

Tel: +44 (0) 1753 285802

Derren Stroud, Chief Financial Officer and Company Secretary

Cenkos Securities plc, financial adviser, nominated adviser and broker to TP Group

Tel: +44 (0) 20 7397 8980

Stephen Keys, Mark Connelly, Callum Davidson

Science Group plc

Sarah Cole, Group Legal Counsel & Company Secretary

Jon Brett, Group Finance Director

Tel: +44 (0) 1223 875 200

Stifel Nicolaus Europe Limited, exclusive financial adviser, nominated adviser and joint broker to Science Group ("Stifel")

Nick Adams, Alex Price, Richard Short

Tel: +44 (0) 207710 7600

Publication on website

In accordance with Rule 26.1 of the Code, a copy of this Announcement will be available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on TP Group's website at www.tpgroupglobal.com/investors and on Science Group's website at www.sciencegroup.com/investor-information/, by no later than 12.00 noon (London time) on 25 January 2023.

The content of the website referred to above is not incorporated into and does not form part of this Announcement.

Important notice

 

This Announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, whether pursuant to this Announcement or otherwise, or the solicitation of any vote or approval of any offer in any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction and any such offer (or solicitation) may not be extended in any such jurisdiction.

Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended, or with any securities regulatory authority of any state of the United States and may not be offered or sold in the United States absent registration or an applicable exemption from registration thereunder.

This Announcement has been prepared in accordance with the laws of England and Wales, the AIM Rules and the Takeover Code, and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in accordance with the laws of jurisdictions outside England and Wales. The distribution of this Announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this Announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

Cenkos, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to TP Group and no one else in connection with the Acquisition and the other matters referred to in this Announcement. In connection with such matters, Cenkos will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to clients of Cenkos or for providing advice in relation to the Acquisition or any other matters referred to in this Announcement.

Stifel, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser and joint broker exclusively to Science Group and no one else in connection with the Acquisition and the other matters referred to in this Announcement. In connection with such matters, Stifel will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to clients of Stifel or for providing advice in relation to the Acquisition or any other matters referred to in this Announcement.

Liberum, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as joint broker exclusively for Science Group and no one else in connection with the Acquisition and the other matters referred to in this Announcement. In connection with such matters, Liberum will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to clients of Liberum or for providing advice in relation to the Acquisition or any other matters referred to in this Announcement.

Disclosure requirements of the Takeover Code (the "Code")

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SOANKQBDQBKDODB
Date   Source Headline
27th Jan 20237:00 amRNSCancellation - TP Group Plc
26th Jan 202310:16 amRNSForm 8.5 (EPT/NON-RI) - TP Group PLC
26th Jan 202310:05 amRNSScheme Effective
26th Jan 20237:30 amRNSSuspension - TP Group Plc
25th Jan 20239:20 amRNSForm 8.5 (EPT/NON-RI)
24th Jan 20232:21 pmRNSCourt Sanction of Scheme of Arrangement
24th Jan 20238:55 amRNSForm 8.5 (EPT/NON-RI)
23rd Jan 20235:30 pmRNSTP Group
20th Jan 20239:05 amRNSForm 8.5 (EPT/NON-RI)
19th Jan 20238:26 amRNSForm 8.5 (EPT/NON-RI)
18th Jan 202312:11 pmRNSForm 8.3 - TP Group plc
18th Jan 202312:09 pmRNSForm 8.3 - TP Group plc
18th Jan 20238:37 amRNSForm 8.5 (EPT/NON-RI)
17th Jan 20238:45 amRNSForm 8.5 (EPT/NON-RI)
16th Jan 202312:53 pmRNSForm 8.3 - TP Group plc
16th Jan 20238:40 amRNSForm 8.5 (EPT/NON-RI)
13th Jan 20239:03 amRNSForm 8.5 (EPT/NON-RI)
12th Jan 20238:46 amRNSForm 8.5 (EPT/NON-RI)
11th Jan 20239:38 amRNSForm 8.5 (EPT/NON-RI)
10th Jan 20239:11 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20238:36 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20237:00 amRNSRegulatory Clearance & Scheme Timetable Update
6th Jan 20238:25 amRNSForm 8.5 (EPT/NON-RI)
5th Jan 20238:17 amRNSForm 8.5 (EPT/NON-RI)
4th Jan 20239:14 amRNSForm 8.5 (EPT/NON-RI) - TP Group PLC
29th Dec 20223:04 pmRNSSale of Westek Technology Ltd.
29th Dec 20228:44 amRNSForm 8.5 (EPT/NON-RI)
22nd Dec 20228:56 amRNSForm 8.5 (EPT/NON-RI)
21st Dec 202212:22 pmRNSHolding(s) in Company
21st Dec 20229:22 amRNSForm 8.5 (EPT/NON-RI)
20th Dec 202211:10 amRNSForm 8.5 (EPT/NON-RI)
19th Dec 202210:23 amRNSForm 8.5 (EPT/NON-RI)
19th Dec 20229:29 amRNSForm 8.3 - TP Group PLC
15th Dec 20228:58 amRNSForm 8.5 (EPT/NON-RI)
14th Dec 20223:33 pmRNSResult of Court Meeting & General Meeting
14th Dec 202210:26 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 20228:34 amRNSForm 8.5 (EPT/NON-RI)
7th Dec 202210:46 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20228:54 amRNSForm 8.5 (EPT/NON-RI)
2nd Dec 202210:02 amRNSForm 8.5 (EPT/NON-RI)
1st Dec 20229:55 amRNSForm 8.5 (EPT/NON-RI)
1st Dec 20228:15 amRNSForm 8.3 -TP Group PLC
30th Nov 20228:54 amRNSForm 8.5 (EPT/NON-RI)
29th Nov 20228:14 amRNSForm 8.3 - TP GROUP PLC
28th Nov 20228:22 amRNSForm 8.3 - TP Group PLC
24th Nov 202210:39 amRNSForm 8.5 (EPT/NON-RI)
24th Nov 20228:28 amRNSForm 8.3 - TP GROUP PLC
23rd Nov 20228:48 amRNSForm 8.3 - TP GROUP PLC
22nd Nov 20229:45 amRNSForm 8.5 (EPT/NON-RI)
22nd Nov 20228:26 amRNSForm 8.3 - TP GROUP PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.